The U.S. Food and Drug Administration approved Scynexis Inc.’s Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections.
https://www.pharmalive.com/wp-content/uploads/2021/06/Brexafemme-Scynexis.jpeg13191430Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-06-02 07:30:312021-06-02 12:27:00U.S. FDA Approves Brexafemme for VVC